Efficacy of a betamethasone dipropionate topical glycol preparation in the management of severe psoriasis.
A multicenter, double-blind clinical evaluation of three formulations of betamethasone dipropionate was conducted in 258 patients with severe psoriasis. The results obtained after a standard two-week treatment period clearly indicated that a new glycol preparation produced significantly greater improvement than the ointment and cream formulations currently in clinical use. Twenty-one percent of the patients treated with the new formulation had clearing of all signs and symptoms of psoriasis within the two-week span. Sixty-eight percent of those treated with this new preparation reported complete disappearance of scaling, the major cosmetically disturbing sign of the disease. Adverse drug effects were uncommon and were of a limited dermatologic nature. They were equally distributed among treatment groups
D000287:Administration, Topical; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011409:Propylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*
D011409:Propylene Glycols; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone